Clinical trials: Pulmonary Infection
Covid19
Study to Reinforce Immunity (STRI) Phase 2 Clinical Trial
Protocol STRI12 - Study to Reinforce Immunity (STRI) - A Phase 2 Double-Blind, Randomized, Placebo-Controlled Study to Investigate the Safety and Efficacy of STRI Formula in Non-Hospitalized Participants with COVID-19 (the Study)
- Trial name
- NCT05046561
- Testing
- STRI Formula
- Where
- 13 sites in United States
- Volunteers
- 598 people
- Sponsor
- Eyecheck, Inc.
Post Acute COVID-19 Syndrome, Long COVID
Safety, Tolerability and Efficacy of S-1226 in Post-COVID-19 Subjects With Persistent Respiratory Symptoms.
This is a randomized (1:1) , placebo-controlled phase II study to evaluate the safety, tolerability and efficacy of S-1226 in Post-COVID-19 subjects (n≤48) with persistent respiratory symptoms.
- Conditions
- Post Acute COVID-19 Syndrome, Long COVID, COVID-19 Respiratory Infection
- Trial name
- NCT04949386
- Testing
- S-1226 (8%)
- Volunteers
- 48 people
- Sponsor
- SolAeroMed Inc.
COVID-19, SARS-CoV-2 Acute Respiratory Disease
Assessing the Immunogenicity and Safety of a HIPRA's Candidate Booster Vaccination in Adults Fully Vaccinated With Adenovirus Vaccine Against COVID-19.
Phase IIb clinical trial to assess the Immunogenicity and Safety of a HIPRA's Candidate Booster vaccination (PHH-1V) in adults fully vaccinated with the adenovirus vaccine Vaxevria against COVID-19.
- Trial name
- NCT05305573
- Testing
- COVID-19 Vaccine HIPRA 40 ug/dose, Comirnaty (Pfizer-BioNtech) 30 ug/dose concentrate for dispersion for injection
- Where
- 7 sites in Spain
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Hipra Scientific, S.L.U
Covid19
Evaluation of a COVID-19 Pneumonia CXR AI Detection Algorithm
This study investigates the diagnostic performance of an AI algorithm in the detection of COVID-19 pneumonia on chest radiographs.
- Trial name
- NCT04561024
- Testing
- AI model
- Where
- Hong Kong
- Volunteers
- 4,000 people, healthy volunteers welcome
- Sponsor
- Ensemble Group Holdings, LLC
COVID-19
TCM Differentiation and Treatment Protocol of COVID-19
Evaluation of the efficacy and safety of TCM differential treatment of COVID-19 in Jiangsu Province based on the historical prospective multicenter cohort study.
- Trial name
- TDATPOC (NCT04306497)
- Testing
- TCM prescriptions
- Where
- China
- Volunteers
- 340 people
- Sponsor
- Jiangsu Famous Medical Technology Co., Ltd.
COVID-19
A Dose Finding, Efficacy and Safety Study of Ensovibep (MP0420) in Ambulatory Adult Patients With Symptomatic COVID-19
The purpose of this study is to establish the antiviral efficacy of ensovibep against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in humans, identify the optimal dose, and demonstrate its clinical value for…
- Trial name
- EMPATHY (NCT04828161)
- Testing
- ensovibep
- Where
- 48 sites in United States, Hungary and 3 more
- Volunteers
- 407 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Obstructive Pulmonary Disease, Bronchitis
Safety and Efficacy of Arformoterol Tartrate Inhalation Solution in Subjects With Chronic Obstructive Pulmonary Disease
To evaluate the long-term safety and monitor the long-term efficacy of arformoterol over a period of 6 months in subjects with chronic obstructive pulmonary disease (COPD).
- Conditions
- Chronic Obstructive Pulmonary Disease, Bronchitis, Emphysema
- Trial name
- NCT00250679
- Testing
- Arformoterol tartrate inhalation solution, Arformoterol 25 ųg BID, Formoterol 12 ųg BID
- Where
- 60 sites in United States
- Volunteers
- 443 people
- Sponsor
- Sumitomo Pharma America, Inc.
COVID-19
Evaluation of the Safety and Immunogenicity of a SARS-CoV-2 rS Nanoparticle Vaccine With/Without Matrix-M Adjuvant
2019nCoV-101 is a 2-part, randomized, observer-blinded, placebo-controlled, Phase 1/2 trial. Part 1 (Phase 1) of the study is designed to evaluate the safety and immunogenicity of SARS-CoV-2 rS nanoparticle vaccine with or…
- Trial name
- NCT04368988
- Testing
- SARS-CoV-2 rS - Phase 1, SARS-CoV-2 rS/Matrix-M Adjuvant - Phase 1, SARS-CoV-2 rS/Matrix-M Adjuvant, Day 0 - Phase 1
- Where
- 18 sites in United States, Australia
- Volunteers
- 1,419 people, healthy volunteers welcome
- Sponsor
- Novavax
Pulmonary Disease, Chronic Obstructive, Pulmonary Emphysema
PROCHYMAL™ (Human Adult Stem Cells) for the Treatment of Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
The objective of the present study is to establish the safety and efficacy of multiple administrations of Prochymal™(ex-vivo cultured human adult mesenchymal stem cells) in participants with moderate to severe chronic obstructive…
- Conditions
- Pulmonary Disease, Chronic Obstructive, Pulmonary Emphysema, Chronic Bronchitis
- Trial name
- NCT00683722
- Testing
- Prochymal™
- Where
- 6 sites in United States
- Volunteers
- 62 people
- Sponsor
- Mesoblast, Inc.
COVID-19
Drug Use Investigation of COMIRNATY Intramuscular Injection
Post-marketing study, Chotor study of COMIRNATY vaccenees followed for 11months. Serious adverse events and COVID-19 observed during the follow-up period will be collected, and the long-term safety of this product will be…
- Trial name
- NCT04815031
- Testing
- BNT162b2
- Where
- Japan
- Volunteers
- 14,570 people, healthy volunteers welcome
- Sponsor
- Pfizer
Stress, Psychological, Loneliness
Ecological Momentary Assessment and Text Message Intervention for Stress Management
Feasibility and acceptability of an Ecological Momentary Assessment (EMA) compared with an EMA plus automated text message intervention for stress management
- Conditions
- Stress, Psychological, Loneliness, Covid19, Stress
- Trial name
- NCT04907942
- Testing
- EMA + EMA and FACE Stress, EMA Alone
- Where
- United States
- Volunteers
- 81 people, healthy volunteers welcome
- Sponsor
- Click Therapeutics, Inc.
Coronavirus Disease (COVID-19)
Dose Ranging Trial to Assess Safety and Immunogenicity of V590 (COVID-19 Vaccine) in Healthy Adults (V590-001)
The primary objective of this study is to evaluate the safety and tolerability of V590 versus placebo and to assess the immunogenicity of V590 on Day 28.
- Trial name
- NCT04569786
- Testing
- V590
- Where
- 7 sites in United States
- Volunteers
- 232 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
COVID-19 Pneumonia, COVID-19 Respiratory Infection
Phase 2/Phase 3 Study To Evaluate The Efficacy And Safety Of Ramatroban Along With The Standard Of Care In Subjects Hospitalized For COVID Pneumonia
Phase II/Phase III study to evaluate the safety and efficacy of Ramatroban 75 mg tablet against Placebo in subjects hospitalized for pneumonia due to SARS-CoV-2 infection.
- Trial name
- NCT05706454
- Testing
- Ramatroban
- Where
- 7 sites in India
- Volunteers
- 324 people
- Sponsor
- KARE Biosciences
COVID-19
To Evaluate the Safety and Efficacy of Inhaled CT-P63 and CT-P66 Combination Therapy in Symptomatic Patients With COVID-19 Not Requiring Supplemental Oxygen
This is a Phase 3 study to assess the efficacy about therapeutic effect of inhaled CT-P63 and CT-P66 combination therapy to symptomatic patiemts with COVID-19 and overall safety.
- Trial name
- NCT05224856
- Sponsor
- Celltrion
Pneumonia, Bacterial
A Trial to Evaluate the Safety and Immune Response of an Investigational Pneumococcal Vaccine in Adults 50 To 64 Years of Age
This clinical study is designed to evaluate an investigational pneumococcal vaccine named Pn-MAPS30plus. The vaccine is designed to stimulate the immune system to produce antibodies against various serotypes of the S.
- Trial name
- NCT07105722
- Testing
- Pn-MAPS30plus, PCV20
- Where
- 4 sites in Australia
- Volunteers
- 127 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Infections, Bacterial
To Evaluate Plasma and Pulmonary Pharmacokinetics of GSK2140944
Antimicrobial penetration can be assessed through evaluation of antimicrobial concentrations in various lung compartments, including bronchial mucosal tissue, epithelial lining fluid (ELF), and alveolar macrophages (AM).
- Trial name
- NCT01934205
- Testing
- GSK2140944 (Single dose), GSK2140944 (Multiple dose)
- Where
- United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Pneumonia, Pneumocystis Carinii, HIV Infections
A Double-Blind Placebo-Controlled Group Comparative Study To Evaluate the Safety and Effectiveness of Aerosol Pentamidine in the Prophylaxis of Pneumocystis Carinii Pneumonia in Patients With AIDS Post First Episode PCP
To evaluate and compare the safety, tolerability, and efficacy of biweekly administration of aerosol pentamidine versus placebo when used as a prophylactic agent in patients who have recovered from their first episode of…
- Trial name
- NCT00002053
- Testing
- Pentamidine isethionate
- Where
- United States
- Sponsor
- Fisons
Pneumonia
Study to Compare the Efficacy of Pristinamycin (Pyostacine ®) Versus Amoxicillin in the Treatment of Acute Community Acquired Pneumonia
Primary Objective: To evaluate the clinical efficacy of pristinamycin at a dose of 2g x 2/day for 2 days then 1g x 3/day for 5 to 7 days versus amoxicillin 1g x3 /day for 7 to 9 days, 5 to 9 days after the end of treatment.
- Trial name
- NCT02332577
- Testing
- PRISTINAMYCIN XRP7263, Amoxicillin
- Where
- 19 sites in France, Tunisia
- Volunteers
- 161 people
- Sponsor
- Sanofi
SARS-CoV-2 Infection, Influenza A
Usability and Clinical Validation of the Flu A/B/COVID-19 + RSV Multiplex Rapid Test
This will be a prospective study for the clinical validation of the CorDx Tyfast Flu A/B/COVID-19 + RSV Multiplex Rapid Test for the qualitative detection and differentiation of SARS-CoV-2, Influenza A, Influenza B and RSV in AN…
- Conditions
- SARS-CoV-2 Infection, Influenza A, Influenza B, RSV
- Trial name
- CorDx 4in1 (NCT07875270)
- Testing
- Flu A/B/COVID-19 + RSV Multiplex Rapid Test
- Where
- United States
- Volunteers
- 1,500 people
- Sponsor
- CorDx, Inc.
Community-acquired Bacterial Pneumonia
Efficacy and Safety Study of Oral Solithromycin (CEM-101) Compared to Oral Moxifloxacin in Treatment of Patients With Community-Acquired Bacterial Pneumonia
This study will evaluate the safety and efficacy of an experimental antibiotic, solithromycin, in the treatment of adult patients with community-acquired pneumonia.
- Trial name
- SOLITAIRE-ORAL (NCT01756339)
- Testing
- Solithromycin, Moxifloxacin
- Where
- 119 sites in United States, Argentina and 15 more
- Volunteers
- 860 people
- Sponsor
- Melinta Therapeutics, Inc.